Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

Abstract

Outcomes in older patients with acute myeloid leukemia (AML) have historically been poor. Given advances in low‐intensity therapy (LIT) and stem cell transplantation (SCT), we performed a retrospective single‐center study to evaluate the contemporary outcomes of this population. We reviewed all patients ≥60 years with newly diagnosed AML between 2012 and 2021 and analyzed treatment and SCT‐related trends and outcomes. We identified 1073 patients with a median age of 71 years. Adverse clinical and cytomolecular findings were frequent within this cohort. In total, 16% of patients were treated with intensive chemotherapy, 51% with LIT alone, and 32% with LIT plus venetoclax. The composite complete remission rate with LIT plus venetoclax was 72%, which was higher than with LIT alone (48%, p < .0001) and comparable to intensive chemotherapy (74%, p = .6). The median overall survival (OS) with intensive chemotherapy, LIT, and LIT plus venetoclax was 20.1, 8.9, and 12.1 months, respectively. 18% of patients received SCT. SCT rates were 37%, 10%, and 22% in patients treated with intensive chemotherapy, LIT, and LIT plus venetoclax, respectively. The 2‐year OS, relapse‐free survival (RFS), cumulative incidence (CI) of relapse, and CI of treatment‐related mortality with frontline SCT (n = 139) were 59%, 52%, 27%, and 22%, respectively. By landmark analysis, patients undergoing frontline SCT had superior OS (median 39.6 vs. 21.4 months, p < .0001) and RFS (30.9 vs. 12.1 months, p < .0001) compared with responding patients who did not. Outcomes in older patients with AML are improving with more effective LIT. Measures should be pursued to increase access to SCT in older patients.

Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations

“…Acute myeloid leukemia (AML) is an aggressive malignancy characterized by proliferation of immature leukemia cells in the bone marrow [1,2]. Relatively young and fit patients can be cured by intensive chemotherapy, possibly combined with allogeneic stem cell transplantation, although only approximately half of the patients receiving this treatment achieve long-term AML-free survival [3,4]. Furthermore, elderly and unfit patients cannot receive such intensive therapy due to unacceptable risk of severe toxicity/treatment-related mortality, and many of these patients receiving only supportive or disease-stabilizing 2 of 23 therapy (including targeted therapies) survive for less than half a year after diagnosis [2][3][4].…”